Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

57.1%

8 terminated/withdrawn out of 14 trials

Success Rate

42.9%

-43.6% vs industry average

Late-Stage Pipeline

14%

2 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results6 terminated

Enrollment Performance

Analytics

Phase 1

9(64.3%)

Phase 2

3(21.4%)

Phase 3

2(14.3%)

14Total

Phase 1(9)

Phase 2(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT03547115Phase 1Terminated

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Role: lead

NCT03768505Phase 2Terminated

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Role: lead

NCT05824559Phase 1Terminated

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Role: lead

NCT04745832Phase 3Terminated

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Role: lead

NCT05604417Phase 1Withdrawn

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Role: collaborator

NCT02914938Phase 1Terminated

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Role: lead

NCT05209308Phase 2Withdrawn

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Role: lead

NCT02100007Phase 1Terminated

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

Role: lead

NCT02521389Phase 1Completed

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143

Role: lead

NCT00382811Phase 3Completed

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

Role: lead

NCT00091377Phase 1Completed

Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Role: lead

NCT01544322Phase 1Completed

Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors

Role: lead

NCT01401868Phase 1Completed

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

Role: lead

NCT00557037Phase 2Completed

A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer

Role: lead

All 14 trials loaded